XIAO FANG ORD A (SHH) EQSW Exp:
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. produces and sells medicines in China. It offers medicines in the areas of gastroenterology, dermatology, orthopedics and traumatology, five senses, and disinfection. Shanghai Xiao Fang Pharmaceutical Co.,Ltd. was founded in 1993 and is based in Shanghai, China.
XIAO FANG ORD A (SHH) EQSW Exp: (603207) - Net Assets
Latest net assets as of June 2025: CN¥1.12 Billion CNY
Based on the latest financial reports, XIAO FANG ORD A (SHH) EQSW Exp: (603207) has net assets worth CN¥1.12 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.25 Billion) and total liabilities (CN¥137.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.12 Billion |
| % of Total Assets | 89.04% |
| Annual Growth Rate | 75.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.45 |
XIAO FANG ORD A (SHH) EQSW Exp: - Net Assets Trend (2021–2024)
This chart illustrates how XIAO FANG ORD A (SHH) EQSW Exp:'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XIAO FANG ORD A (SHH) EQSW Exp: (2021–2024)
The table below shows the annual net assets of XIAO FANG ORD A (SHH) EQSW Exp: from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.23 Billion | +112.82% |
| 2023-12-31 | CN¥579.95 Million | +55.75% |
| 2022-12-31 | CN¥372.36 Million | +62.53% |
| 2021-12-31 | CN¥229.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to XIAO FANG ORD A (SHH) EQSW Exp:'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1133.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥532.86 Million | 43.17% |
| Other Components | CN¥701.37 Million | 56.83% |
| Total Equity | CN¥1.23 Billion | 100.00% |
XIAO FANG ORD A (SHH) EQSW Exp: Competitors by Market Cap
The table below lists competitors of XIAO FANG ORD A (SHH) EQSW Exp: ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
$200.27 Million |
|
Ribbon Communications Inc
NASDAQ:RBBN
|
$200.29 Million |
|
Chengdu Screen Micro-Electronics Co. Ltd. A
SHG:688053
|
$200.36 Million |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
$200.37 Million |
|
Zhe Jiang Li Zi Yuan Food Co Ltd
SHG:605337
|
$200.24 Million |
|
Performant Financial Corporation
NASDAQ:PFMT
|
$200.24 Million |
|
Sky Network Television Ltd
AU:SKT
|
$200.24 Million |
|
Eimskipafélag Íslands hf
IC:EIM
|
$200.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XIAO FANG ORD A (SHH) EQSW Exp:'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 579,954,208 to 1,234,234,682, a change of 654,280,474 (112.8%).
- Net income of 205,271,096 contributed positively to equity growth.
- Other factors increased equity by 449,009,379.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥205.27 Million | +16.63% |
| Other Changes | CN¥449.01 Million | +36.38% |
| Total Change | CN¥- | 112.82% |
Book Value vs Market Value Analysis
This analysis compares XIAO FANG ORD A (SHH) EQSW Exp:'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.77x to 3.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥1.91 | CN¥28.20 | x |
| 2022-12-31 | CN¥3.10 | CN¥28.20 | x |
| 2023-12-31 | CN¥4.83 | CN¥28.20 | x |
| 2024-12-31 | CN¥7.71 | CN¥28.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XIAO FANG ORD A (SHH) EQSW Exp: utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.63%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 43.25%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.14x
- Recent ROE (16.63%) is below the historical average (38.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 55.11% | 31.43% | 1.04x | 1.68x | CN¥103.36 Million |
| 2022 | 47.05% | 38.34% | 0.99x | 1.24x | CN¥137.94 Million |
| 2023 | 35.11% | 43.15% | 0.66x | 1.23x | CN¥145.63 Million |
| 2024 | 16.63% | 43.25% | 0.34x | 1.14x | CN¥81.85 Million |
Industry Comparison
This section compares XIAO FANG ORD A (SHH) EQSW Exp:'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XIAO FANG ORD A (SHH) EQSW Exp: (603207) | CN¥1.12 Billion | 55.11% | 0.12x | $200.26 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |